January 30, 2023

Aprea Therapeutics Appoints John Hamill as Chief Financial Officer

DOYLESTOWN, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel sy...
Read more
January 23, 2023

Priothera announces first patients enrolled in pivotal MO-TRANS global Phase 2b/3 study with mocravimod as an adjunctive and maintenance therapy for patients with Acute Myeloid Leukemia (AML) undergoing allogeneic Hematopoietic Cell Transplant (HCT)

Mocravimod is the only S1PR modulator being developed to treat blood cancers and improve CAR-T therapy  Phase 1b/2a data has shown mocravimod is safe and well tolerated ...
Read more
January 11, 2023

Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors

DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthe...
Read more
January 11, 2023

Oncopeptides appoints Holger Lembrer as Chief Financial Officer

STOCKHOLM — January 11, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hema...
Read more
January 10, 2023

Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia

Bispecific antibody HMB-001 positioned as the first prophylactic treatment for rare bleeding disorders CEO Benny Sorensen, MD, PhD, delivered the update during a corporate...
Read more
January 9, 2023

Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Topline Results from CAHmelia-203 in Adult Classic Congenital Adrenal Hyperplasia (CAH) Anticipated in 2H 2023 Amendment to Phase 2 CAHptain Clinical Trial in Pediatric Classic...
Read more
January 5, 2023

Fusion Pharmaceuticals And BWXT Medical Announce Actinium-225 Partnership To Scale Supply For Developing Targeted Alpha Therapies

-  Agreement augments Fusion's existing isotope supply as pipeline of clinical stage actinium-based radiopharmaceuticals grows -  Furthers BWXT Medical's position as...
Read more
January 5, 2023

Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan

Partnership aims to accelerate global development and commercialization plans for tildacerfont to address worldwide unmet medical need in congenital adrenal hyperplasia (CAH) D...
Read more
January 5, 2023

Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

Adcendo licenses Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program Agreement based on synergies between Adce...
Read more
January 4, 2023

Monica Shaw appointed CEO of Oncopeptides – Jakob Lindberg assumes position as Chief Scientific Officer

STOCKHOLM — January 4, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hemat...
Read more
Older news →